Hexa Reports Industry Spinal Muscular Atrophy (SMA) Market

Spinal Muscular Atrophy (SMA) Market Size, Outlook and
Perspective Analysis by 2017
“Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells,
called motor neurons, in the spinal cord. These critically important cells are
responsible for supplying electrical and chemical messages to muscle cells.”
Spinal Muscular Atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the
spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to
muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The
muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness.
This can affect walking, crawling, breathing, swallowing, and head and neck control.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Spinal Muscular Atrophy (SMA) Pipeline Review, H2 2017,
provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy
(SMA) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and development history and latest news
and press releases.
Browse Detail Report With TOC @
https://www.hexareports.com/report/spinal-muscular-atrophy-sma-pipeline-review-h2-2017
Follow Us: